Company

BeOne Medicines

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 19, 2026 · PHASE 3 TRIAL

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results posted; the study is still recruiting and outcomes are not yet reported.

PreliminaryPalbociclib BeOne Medicines Letrozole

Reported

PhasePhase 3

Planned enrollment1056

Primary outcome measureProgression-Free Survival (PFS) Determined…

AUG 19, 2026 · PHASE 1 TRIAL

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

ClinicalTrials.gov

This is a Phase 1 dose-escalation and dose-expansion trial registration with no results posted; it is a first-in-human safety and tolerability study designed to establish dosing, not efficacy.

PreliminaryBeOne Medicines Elacestrant Advanced Breast Cancer

Reported

Estimated enrollment399

Study phasePhase 1

Primary outcome (Phase 1a)Number of Participants with Adverse Events…

AUG 14, 2026 · PHASE 1 TRIAL

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

ClinicalTrials.gov

Phase 1 trial in early-stage development assessing safety and preliminary antitumor activity; no results reported in this registry record.

PreliminaryBeOne Medicines NCT07222267 Estrogen Receptor Antagonist

Reported

Estimated enrollment86

PhasePhase 1

Primary outcome: Adverse events f…From first dose to 30 days after last dose…